Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinghua Bihui is a traditional Chinese medicine (TCM) formulation developed and used in China, notably during the COVID-19 pandemic in Shanghai to help prevent and control the epidemic. It is administered as granules or decoctions. The formula consists of multiple TCM herbs, though the exact composition is not specified in available sources. Its mechanism of action is believed to involve immunomodulation and anti-inflammatory effects typical of TCM formulas used for respiratory infections. Clinical trials have been conducted to evaluate its efficacy and safety for mild COVID-19 cases[1][3]. The product has been produced at scale for public health interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinghua Bihui.